Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs BioMarin Pharmaceutical Inc. (BMRN)

BridgeBio Pharma, Inc. and BioMarin Pharmaceutical Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $13.1B against $10.9B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; BioMarin Pharmaceutical Inc. trades at 144×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 11.2%. BioMarin Pharmaceutical Inc. has the higher net margin (2.14% vs −97.0%) and the higher return on invested capital (0.97% vs 0.00%). Across the 18 metrics below, BioMarin Pharmaceutical Inc. leads on 11 and BridgeBio Pharma, Inc. on 7.

Valuation

Metric BBIO BMRN Biotechnology median
P/E n/m 143.89 8.50
P/S 18.23 3.10 9.71
P/B n/m 1.67 2.13
Price to free cash flow n/m 14.59 20.82
EV/EBITDA n/m 46.69 0.64
EV/Sales 19.93 4.08 9.21
Earnings yield (5.38%) 0.69% (33.15%)
Free cash flow yield (3.41%) 6.85% (25.50%)

Profitability

Metric BBIO BMRN Biotechnology median
Gross margin 94.44% 76.12% 65.16%
Operating margin (69.81%) 4.38% 0.00%
Net margin (97.03%) 2.14% 0.00%
Free cash flow margin (61.06%) 21.28% 0.00%
Return on equity 32.31% 1.18% (56.36%)
Return on assets (60.23%) 0.76% (48.04%)
Return on invested capital 0.00% 0.97% 0.00%

Growth

Metric BBIO BMRN Biotechnology median
Revenue growth (TTM) 202.39% 11.20% 6.02%
EPS growth (last fiscal year) (31.25%) (18.55%) 30.26%
Revenue growth, 5-year CAGR 127.44% 11.60% 9.41%
Net income growth, 5-year CAGR 0.00% (16.39%) 0.00%

Health

Metric BBIO BMRN Biotechnology median
Debt to equity (0.77) 0.66 0.00
Current ratio 1.23 2.39 4.72
Net debt to EBITDA (2.47) (1.99) 0.96

Dividend

Metric BBIO BMRN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBIO BMRN Biotechnology median
Market cap 13.12b 10.85b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack